Protein Design halts trial; proposes financing

PDLI said the FDA has asked that the company put its Phase II trial of SMART anti-CD3 antibody to prevent kidney transplant rejection on hold after the company requested that the agency approve a dosing modification based on preliminary data. The FDA has asked PDLI for additional data on the antibody. The antibody is in ongoing Phase I/II studies to treat psoriasis and graft-versus-host disease. ...